This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinico-pathological classification

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Malignant melanomas undergo two growth phases - radial and vertical. Vertical invasion is a poor prognostic sign.

Different types may be recognised - Clark (1969):

  • superficial spreading (70%)
  • nodular (15%)
  • lentigo maligna (4-15%)
  • acral lentiginous including periungual (5%)
  • amelanotic melanoma (1)

Histologically and cytologically, there are several features that distinguish malignant melanomas:

  • size:
    • most malignant melanomas are greater than 10mm in diameter
    • most benign tumours are less than 6mm
  • symmetry: malignant lesions are usually asymmetrical with respect to cell type, extension and degree of pigmentation
  • ascent of melanocytes: malignant tumours show melanocytes travelling upwards at the lateral margins of the tumour
  • epidermal hyperplasia: commonly seen with malignant lesions
  • dermal growth:
    • malignant melanomas vary in their cell type and architecture in different parts of the tumour
    • benign lesions are regular in appearance and change to smaller cells within the depth of the lesion
  • cytology: with increasing malignancy, there is a wider variation in cell shape and amount of pigment contained withing the melanocyte

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.